Clinical Trial Detail

NCT ID NCT03349710
Title Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

hypopharynx cancer

oral squamous cell carcinoma

head and neck squamous cell carcinoma

oropharynx cancer

laryngeal squamous cell carcinoma

Therapies

Cetuximab

Cisplatin

Cetuximab + Nivolumab

Cisplatin + Nivolumab

Age Groups: adult senior

No variant requirements are available.